



CONTACTS

Matthew Bennett
Ikaria
908-238-6673
matthew.bennett@ikaria.com

Elizabeth Scott
The Ruth Group
646-536-7014
escott@theruthgroup.com

IKARIA TO PRESENT AT 26th ANNUAL JPMORGAN HEALTHCARE CONFERENCE

Clinton, NJ, January 3, 2008 – Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that its Chairman & CEO, David Shaw, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 3:00 p.m., PST. The conference will be held January 7-10 at The Westin St. Francis Hotel in San Francisco.

About INOmax

INOmax, in conjunction with ventilatory support and other appropriate agents, is used for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension.

INOmax is designed to help critically ill newborns breathe more effectively by dilating the blood vessels of the lungs, which improves oxygen uptake and oxygen supply to the tissues of the body. INOmax therapy has been shown to reduce the need for a highly invasive surgical procedure known as extracorporeal membrane oxygenation, or ECMO. During ECMO, an infant's blood is mechanically oxygenated by connecting the baby to a heart-lung machine.

INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO₂) forms rapidly in gas mixtures containing nitric oxide and oxygen and thus may cause airway inflammation and damage. Methemoglobin, NO₂, and the fraction of inspired oxygen (FiO₂) should be monitored during nitric oxide administration.

For more information on INOmax, including important safety and complete prescribing information, please visit INOmax.com

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax[®] (nitric oxide) for inhalation, is an FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox[®] (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H₂S) for various indications. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit www.ikaria.com.

###